相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems
Patrick M. Glassman et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads
Jayesh A. Kulkarni et al.
NANOSCALE (2019)
The Adipose Stromal Vascular Fraction as a Complex Cellular Source for Tissue Engineering Applications
Venkat M. Ramakrishnan et al.
TISSUE ENGINEERING PART B-REVIEWS (2018)
Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs
Siva Sai Krishna Dasa et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles
Yuan Xue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Prohibition in Adipose and Immune Functions
Sudharsana R. Ande et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2016)
Onivyde for the therapy of multiple solid tumors
Haijun Zhang
ONCOTARGETS AND THERAPY (2016)
Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue
Ahmad Salameh et al.
JCI INSIGHT (2016)
Treatment in vitro with PPARα and PPARγ ligands drives M1-to-M2 polarization of macrophages from T. cruzi-infected mice
Federico Penas et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2015)
Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction
Siva Sai Krishna Dasa et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Prohibitin is involved in the activated internalization and degradation of protease-activated receptor 1
Yan-Jie Wang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Oligopeptide complex for targeted non-viral gene delivery to adipocytes
Young-Wook Won et al.
NATURE MATERIALS (2014)
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review
Bogna Grygiel-Gorniak
NUTRITION JOURNAL (2014)
Intraperitoneal Injection of Clodronate Liposomes Eliminates Visceral Adipose Macrophages and Blocks High-fat Diet-induced Weight Gain and Development of Insulin Resistance
Le Bu et al.
AAPS JOURNAL (2013)
Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Jaymes Beech et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ
Fenfen Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus
Bengt Hamren et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Vascular-targeted nanotherapy for obesity: Unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery
Md Nazir Hossen et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Doxil® - The first FDA-approved nano-drug: Lessons learned
Yechezkel (Chezy) Barenholz
JOURNAL OF CONTROLLED RELEASE (2012)
B Lymphocytes in Human Subcutaneous Adipose Crown-Like Structures
Marie E. McDonnell et al.
OBESITY (2012)
Clodronate Liposomes Improve Metabolic Profile and Reduce Visceral Adipose Macrophage Content in Diet-Induced Obese Mice
Bin Feng et al.
PLOS ONE (2011)
A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys
Kirstin F. Barnhart et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
PPARs: diverse regulators in energy metabolism and metabolic diseases
Yong-Xu Wang
CELL RESEARCH (2010)
Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight
Dong-Hoon Kim et al.
DIABETES (2010)
Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue
Md. Nazir Hossen et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Isolation and culture of microvascular endothelial cells from murine inguinal and epididymal adipose tissues
Kazuaki Kajimoto et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
Peroxisome Proliferator-Activated Receptor Alpha Target Genes
Maryam Rakhshandehroo et al.
PPAR RESEARCH (2010)
How safe is the use of thiazolidinediones in clinical practice?
C. V. Rizos et al.
EXPERT OPINION ON DRUG SAFETY (2009)
Prohibitins and the functional compartmentalization of mitochondrial membranes
Christof Osman et al.
JOURNAL OF CELL SCIENCE (2009)
PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
Shigeki Sugii et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity
Can Pang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance
Herbert Schuster et al.
ATHEROSCLEROSIS (2008)
Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity
Leonie K. Heilbronn et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Prohibitin-1 maintains the angiogenic capacity of endothelial cells by regulating mitochondrial function and senescence
Michael Schleicher et al.
JOURNAL OF CELL BIOLOGY (2008)
PPAR gamma in Kidney Physiology and Pathophysiology
Eva Kiss-Toth et al.
PPAR RESEARCH (2008)
PPARs and the kidney in metabolic syndrome
Xiongzhong Ruan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
The dual peroxisome proliferator-activated receptor α/γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin
Serena Tonstad et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Effect of PPARα activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes
Kentaro Murakami et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Effect of tesaglitazar, a dual PPARα/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes:: a 12-week dose-ranging trial
Barry J. Goldstein et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Tesaglitazar, a dual PPAR α/γ agonist, ameliorates glucose and lipid intolerance in obese Zucker rats
ND Oakes et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2005)
Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population
B Fagerberg et al.
DIABETOLOGIA (2005)
Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration
K Rajalingam et al.
NATURE CELL BIOLOGY (2005)
Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses
A Sharma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Reversal of obesity by targeted ablation of adipose tissue
MG Kolonin et al.
NATURE MEDICINE (2004)
Obesity is associated with macrophage accumulation in adipose tissue
SP Weisberg et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
AZ 242, a novel PPARα/-γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats
B Ljung et al.
JOURNAL OF LIPID RESEARCH (2002)
分享论文
